Skip to main content

Gain Therapeutics, Inc.

GANX
Exchange
Nasdaq
Industry
Pharmaceutical Preparations
SEC CIK
0001819411

No open-market purchases or sales by Gain Therapeutics, Inc. insiders were filed in the last 90 days; 50 institutions reported holding it in 13F filings for Q2 2026, worth $17.4M in total; Greenlight Capital is the only superinvestor holding it.

Q3 2025 vs. Q2 2025

How the institutions holding Gain Therapeutics, Inc. changed between Q2 2025 and Q3 2025.

All holders in Q3 2025All holders in Q2 2025

13F holders of GANX: Q2 2025 compared with Q3 2025
MeasureQ2 2025Q3 2025Change
Holders3538+3
Shares3.79M4.34M+553.8K (+14.6%)
Value$6.49M$7.70M+$1.21M (+18.7%)

New holders (9)

Institutions that held Gain Therapeutics, Inc. at the end of Q3 2025 but not at the end of Q2 2025.

Institutions new to GANX in Q3 2025
InstitutionSharesValue% of portfolio
Jane Street Group, LLC72,450$128.2K0.00%
XTX Topco Ltd54,202$95.9K0.00%
Squarepoint Ops LLC38,537$68.2K0.00%
Two Sigma Securities, LLC27,323$48.4K0.01%
JPMorgan Chase & Co26,280$46.5K0.00%
HRT Financial LP19,717$34.0K0.00%
Wealth Enhancement Advisory Services, LLC15,556$31.4K0.00%
Kestra Advisory Services, LLC12,000$21.2K0.00%
HighTower Advisors, LLC11,574$20.5K0.00%

Sold out (6)

Institutions that held Gain Therapeutics, Inc. at the end of Q2 2025 and filed for Q3 2025 without it.

Institutions that sold out of GANX in Q3 2025
InstitutionShares, Q2 2025Value, Q2 2025
Dauntless Investment Group, LLC46,000$82.8K
Gsa Capital Partners LLP12,756$23.0K
Simplex Trading, LLC5,657$10.0K
Raymond James Financial Inc2,300$4.14K
State of Wyoming1,194$2.15K
Gotham Asset Management, LLC245,896–